Glimepiride/metformin - Sanofi

Drug Profile

Glimepiride/metformin - Sanofi

Alternative Names: Amaryl M; Amaryl M S.R.; Metformin/glimepiride; Solosamet

Latest Information Update: 01 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Developer Handok Inc; Sanofi
  • Class Antihyperglycaemics; Biguanides; Small molecules; Sulfones; Sulfonylureas
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2014 Sanofi completes the phase III LEGEND trial in Type 2 diabetes mellitus in Lebanon, Russia and Ukraine (NCT01699932)
  • 03 Oct 2013 Launched for Type-2 diabetes mellitus in South Korea (PO) some time prior to October 2013
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top